In three metaplastic PDX models with genomic alterations to both the PI3K-AKT-mTOR and RTK-MAPK pathways, we tested a PI3K inhibitor, a MEK inhibitor, their combination, and their association with an anthracycline (usual chemotherapy in breast cancer). This evidence concerns the gene MTOR and breast cancer.